07:48 AM EST, 03/03/2025 (MT Newswires) -- ImmunityBio ( IBRX ) reported Monday it has narrowed its Q4 net loss to $0.09 from $0.35 a year earlier.

Four analysts polled by FactSet expected a loss of $0.20.

Revenue for the quarter ended Dec. 31 was $7.6 million, up from $139,000 a year earlier. Four analysts surveyed by FactSet expected $9.6 million.

ImmunityBio ( IBRX ) shares were up almost 2% in recent premarket activity.